Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer

Launched by WUHAN UNIVERSITY · Apr 10, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for people with locally advanced gastric cancer, which is a type of stomach cancer that hasn't spread to other parts of the body. The goal is to see if combining HIPEC with a major surgery called radical gastrectomy (removing part of the stomach) can help patients live longer compared to just having the surgery alone. The researchers hope that HIPEC can reduce the chances of the cancer coming back in the same area or spreading to other places.

To be eligible for this trial, participants must have a confirmed diagnosis of locally advanced gastric cancer that can still be surgically treated. They should not have any signs of the cancer spreading to distant organs or the lining of the abdomen. Additionally, participants should be eligible for the surgery and have not received other cancer treatments before joining the trial. If someone decides to participate, they will undergo the surgery and receive HIPEC as part of their treatment plan. The trial is currently looking for patients aged between 65 and 75, but it is open to all genders. It’s important for potential participants to discuss with their doctor whether this trial is right for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological proved diagnosis of locally advanced gastric cancer.
• • No evidence of distant metastases or peritoneal metastases.
• • Preoperative examination (CT/MRI) demonstrated resectable gastric cancer with T3-T4 stage.
• • Eligible for radical gastrectomy with D2 lymphadenectomy.
• • Have not received cytotoxic chemotherapy or radiotherapy.
• • Written informed consent is obtained prior to commencement of trial treatment.
• Exclusion Criteria:
• • Existence of distant metastasis or peritoneal metastasis during surgery (M1).
• • Any previous chemotherapy or radiotherapy
• • Active systemic infections
• • Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.
• • Female patients who are pregnant or breast feeding